NCT01648764

A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread

Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 73 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.

Detailed description

This study will consist of a Dose Escalation Phase (Arms A and B) followed by a Dose Confirmation Phase.

Conditions

• Malignant Solid Tumor
• Solid Tumor
• Metastatic Tumor

Interventions

Type	Name	Description
DRUG	LY2334737	Administered orally

Timeline

• Start date: 2008-09-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2012-07-24
• Last updated: 2019-06-17
• Results posted: 2019-06-17

Locations

4 sites across 3 countries: United States, France, Germany